• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Almac expands, to create 229 jobs

Almac expands, to create 229 jobs

June 12, 2013
CenterWatch Staff

Craigavon-based Almac has announced a commercial manufacturing expansion. With the recent completion of a non-GMP drug development facility at the Craigavon site, this expansion represents a total investment of $10.3 million, including financial support from Invest Northern Ireland.  Up to 229 jobs will be created across both projects over the next three years.

The product, a laxative drug, which is contract manufactured by Almac, has recorded sales growth year-on-year throughout the U.K. and Europe. Almac is focusing all production in Northern Ireland, with additional equipment and resources in Craigavon. The investment will deliver blending equipment, an automated packing and integrated cartoning line, which will enable high-volume bulk commercial manufacturing beginning in November 2013.

Its new, 13,400-square-foot formulation development facility and analytical laboratories focuses on tablet and capsule formulations for new early-stage drugs.

 “The marketing and promotion of the product by our contract customer has been very effective and significant growth potential in several new territories, such as China, has been identified,” said Graeme McBurney, president and managing director of the business unit. “Centralizing and expanding our production in Craigavon will mean more cost-effective manufacturing and optimal quality control and distribution.”

 “This investment is good news for Craigavon and will reinforce Northern Ireland’s position in the wider life sciences sector,” said Arlene Foster, enterprise minister. “The 229 new jobs will deliver almost $4 million annually in salaries, bringing an important and positive economic boost which will benefit local people.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing